Dr Reddy's Laboratories EPS - Earnings per Share 2010-2024 | RDY
Dr Reddy's Laboratories annual and quarterly earnings per share history from 2010 to 2024. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Dr Reddy's Laboratories EPS for the quarter ending September 30, 2024 was $0.04, a 83.18% decline year-over-year.
- Dr Reddy's Laboratories EPS for the twelve months ending September 30, 2024 was $0.62, a 14.17% decline year-over-year.
- Dr Reddy's Laboratories 2024 annual EPS was $0.8, a 21.52% increase from 2023.
- Dr Reddy's Laboratories 2023 annual EPS was $0.66, a 76.47% increase from 2022.
- Dr Reddy's Laboratories 2022 annual EPS was $0.37, a 23.03% increase from 2021.
| Dr Reddy's Laboratories Annual EPS |
| 2024 |
$0.80 |
| 2023 |
$0.66 |
| 2022 |
$0.37 |
| 2021 |
$0.30 |
| 2020 |
$0.31 |
| 2019 |
$0.33 |
| 2018 |
$0.18 |
| 2017 |
$0.22 |
| 2016 |
$0.35 |
| 2015 |
$0.42 |
| 2014 |
$0.42 |
| 2013 |
$0.36 |
| 2012 |
$0.32 |
| 2011 |
$0.30 |
| 2010 |
$0.02 |
| 2009 |
$-0.12 |
| Dr Reddy's Laboratories Quarterly EPS |
| 2024-09-30 |
$0.04 |
| 2024-06-30 |
$0.20 |
| 2024-03-31 |
$0.19 |
| 2023-12-31 |
$0.20 |
| 2023-09-30 |
$0.21 |
| 2023-06-30 |
$0.20 |
| 2023-03-31 |
$0.13 |
| 2022-12-31 |
$0.18 |
| 2022-09-30 |
$0.17 |
| 2022-06-30 |
$0.18 |
| 2022-03-31 |
$0.01 |
| 2021-12-31 |
$0.11 |
| 2021-09-30 |
$0.16 |
| 2021-06-30 |
$0.09 |
| 2021-03-31 |
$0.09 |
| 2020-12-31 |
$0.00 |
| 2020-09-30 |
$0.12 |
| 2020-06-30 |
$0.09 |
| 2020-03-31 |
$0.11 |
| 2019-12-31 |
$-0.10 |
| 2019-09-30 |
$0.19 |
| 2019-06-30 |
$0.12 |
| 2019-03-31 |
$0.08 |
| 2018-12-31 |
$0.08 |
| 2018-09-30 |
$0.09 |
| 2018-06-30 |
$0.08 |
| 2018-03-31 |
$0.05 |
| 2017-12-31 |
$0.06 |
| 2017-09-30 |
$0.05 |
| 2017-06-30 |
$0.01 |
| 2017-03-31 |
$0.06 |
| 2016-12-31 |
$0.08 |
| 2016-09-30 |
$0.05 |
| 2016-06-30 |
$0.02 |
| 2016-03-31 |
$0.01 |
| 2015-12-31 |
$0.10 |
| 2015-09-30 |
$0.13 |
| 2015-06-30 |
$0.12 |
| 2015-03-31 |
$0.10 |
| 2014-12-31 |
$0.11 |
| 2014-09-30 |
$0.11 |
| 2014-06-30 |
$0.11 |
| 2014-03-31 |
$0.09 |
| 2013-12-31 |
$0.12 |
| 2013-09-30 |
$0.13 |
| 2013-06-30 |
$0.08 |
| 2013-03-31 |
$0.12 |
| 2012-12-31 |
$0.08 |
| 2012-09-30 |
$0.10 |
| 2012-06-30 |
$0.08 |
| 2012-03-31 |
$0.08 |
| 2011-12-31 |
$0.12 |
| 2011-09-30 |
$0.08 |
| 2011-06-30 |
$0.07 |
| 2011-03-31 |
$0.08 |
| 2010-12-31 |
$0.08 |
| 2010-09-30 |
$0.08 |
| 2010-06-30 |
$0.06 |
| 2010-03-31 |
$0.04 |
| 2009-12-31 |
$-0.14 |
| 2009-09-30 |
$0.06 |
| 2009-06-30 |
$0.06 |
| 2009-03-31 |
$-0.22 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$12.621B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
